The expression of CD30 in anaplastic large cell lymphoma is regulated by nucleophosmin-anaplastic lymphoma kinase-mediated JunB level in a cell type-specific manner

Cancer Research

Volumn 66, Issue 18, 2006, Pages 9002-9008

  Hsu, Faye Yuan Yi ^a   Johnston, Patrick B ^c   Burke, Kathleen A ^a   Zhao, Yi ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; CD30 ANTIGEN; HYBRID PROTEIN; NUCLEOPHOSMIN; ONCOPROTEIN; TRANSCRIPTION FACTOR JUNB; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; LARGE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTO ONCOGENE; TRANSCRIPTION REGULATION; TUMOR GROWTH; WESTERN BLOTTING;

ANTIGENS, CD30; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, LARGE-CELL; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS C-JUN; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANS-ACTIVATION (GENETICS); TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TRANSFECTION;

EID: 33749489416     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-4101     Document Type: Article

References (19)

1. + anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features. Blood 2000;96:3681-95.
2. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49.
3. Falini B, Pulford K, Pucciarini A, et al. Lymphomas expressing ALK fusion protein(s) other than NPM-ALK. Blood 1999;94:3509-15.
4. Bai RY, Ouyang T, Miething C, Morris SW, Peschel C, Duyster J. Nucleophosmin-anaplastic lymphoma kinase associated with anaplastic large-cell lymphoma activates the phosphatidyunositol 3-kinase/Akt antiapoptotic signaling pathway. Blood 2000;96:4319-27.
5. Slupianek A, Nieborowska-Skorska M, Hoser G, et al. Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis. Cancer Res 2001;61:2194-9.
6. Zhang Q, Raghunath PN, Xue L, et al. Multilevel deregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol 2002;168:466-74.
7. Cussac D, Greenland C, Roche S, et al. Nucleophosmin-anaplastic lymphoma kinase of anaplastic large-cell lymphoma recruits, activates, and uses pp60c-src to mediate its mitogenicity. Blood 2004;103:1464-71.
8. Crockett DK, Lin Z, Elenitoba-Johnson KS, Lim MS. Identification of NPM-ALK interacting proteins by tandem mass spectrometry. Oncogene 2004;23:2617-29.
9. Chiarle R, Podda A, Prolla G, Gong J, Thorbecke GJ, Inghirami G. CD30 in normal and neoplastic cells. Clin Immunol 1999;90:157-64.
10. Croager EJ, Gout AM, Abraham LJ. Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene. Am J Pathol 2000;156:1723-31.
11. Watanabe M, Ogawa Y, Ito K, et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am J Pathol 2003;163:633-41.
12. Horte R, Higashihara M, Watanabe T. Hodgkin's lymphoma and CD30 signal transduction. Int J Hematol 2003;77:37-47.
13. Al-Shamkhani A. The role of CD30 in the pathogenesis of haematopoietic malignancies. Curr Opin Pharmacol 2004;4:355-9.
14. Troen G, Nygaard V, Jenssen TK, et al. Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, c-fos, and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma. J Mol Diagn 2004;6:297-307.
15. Horie R, Watanabe M, Ishida T, et al. The NPM-ALK oncoprotein abrogates CD30 signaling and constitutive NF-κB activation in anaplastic large cell lymphoma. Cancer Cell 2004;5:353-64.
16. Hsu FYY, Zhao Y, Anderson WT, Johnston PB. Down regulation of NPM-ALK by siRNA causes anaplastic large cell lymphoma cell growth inhibition and augments the anti-cancer effects of chemotherapy. Cancer Invest In press 2007.
17. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003;3:859-68.
18. + lymphomas and lymphomatoid papulosis. Mod Pathol 2005;10:1365-70.
19. Turner SD, Tooze R, Maclennan K, Alexander DR. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase. Oncogene 2003;22:7750-61.